Skip to main content

Table 1 Baseline characteristics by groups

From: Longitudinal stent elongation or shortening after deployment in the coronary arteries: which is dominant?

   Elongated stents Shortened stents Unchanged stents p value
(n = 69, 67.6%) (n = 16, 15.7%) (n = 17, 16.7%)
Age, years   65.6 ± 10.0 67.6 ± 10 64.8 ± 11.6 0.72
Males   57 (82.6%) 14 (87.5%) 15 (88.2%) 0.92
Smoking   30 (43.5%) 12 (75%) 12 (70.6%) 0.043
Hypertension   42 (60.9%) 12 (75%) 10 (58.8%) 0.77
DM   22 (31.9%) 8 (50%) 4 (23.5%) 0.37
Dyslipidemia   45 (65.2%) 11 (68.8%) 10 (58.8%) 0.8
Family history   7 (10.1%) 4 (25%) 3 (17.6%) 0.28
Clinical presentation      0.27
  AP 29 (42%) 7 (43.8%) 6 (35.3%)  
  UAP 20 (29%) 7 (43.8%) 3 (17.6%)  
  AMI 20 (29%) 2 (12.5%) 8 (47.1%)  
Statin   41 (59.4%) 9 (56.3%) 7 (41.2%) 0.27
Beta blockers   17 (24.6%) 7 (43.8%) 5 (29.4%) 0.39
Calcium antagonists   26 (37.7%) 9 (56.3%) 7 (41.2%) 0.65
ACE-I   16 (23.2%) 5 (31.3%) 4 (23.5%) 0.94
ARB   20 (29%) 4 (25%) 8 (47.1%) 0.28
EF   62.9 ± 11.6 64.0 ± 13.7 55.0 ± 14.7 0.061
Cholesterol, mg/dL   189.5 ± 32.6 192.7 ± 39.8 189.4 ± 47.3 0.95
HDL-cholesterol, mg/dL   49.4 ± 12.6 47.4 ± 12.6 45.3 ± 18.3 0.61
LDL-cholesterol, mg/dL   121.9 ± 31.1 116.2 ± 13.4 114.8 ± 26.3 0.85
Angiographic data:
 Stented vessel      0.37
  LAD 40 (58%) 11 (68.8%) 8 (47.1%)  
  LCX 13 (18.8%) 4 (25%) 3 (17.6%)  
  RCA 16 (23.2%) 1 (6.3%) 6 (35.3%)  
 ACC/AHA lesion type      0.45
  A 31 (44.9%) 8 (50%) 9 (52.9%)  
  B 31 (44.9%) 8 (50%) 8 (47.1%)  
  C 7 (10.1%) 0 0  
 Lesion length, mm   11.3 ± 6.4 9.4 ± 3.8 8.8 ± 3.2 0.18
 Reference diameter, mm   3.1 ± 0.6 3.1 ± 0.7 3.3 ± 0.7 0.45
 MLD, mm   0.8 ± 0.3 0.8 ± 0.3 1.0 ± 0.2 0.15
 DS%   74.1 ± 16.3 71.2 ± 14.9 70.9 ± 6.9 0.65
 Deployment pressure, atm   16.7 ± 3.2 15.1 ± 3.4 16.1 ± 2.8 0.19
 High pressure stenting, >16 atm   49 (71%) 7 (43.8%) 10 (58.8%) 0.105
 Post-stent baloon dilatation   20 (29%) 2 (12.5%) 4 (23.5%) 0.49
IVUS data:
 Reference VA, mm2   15.4 ± 3.8 14.9 ± 3.3 17.4 ± 4.6 0.26
 Reference LA, mm2   9.3 ± 2.2 8.9 ± 2.6 10.8 ± 2.8 0.14
 Proximal site VA, mm2   16.6 ± 5.0* 17.0 ± 4.3 21.7 ± 4.8 0.02
 Proximal site LA, mm2   8.7 ± 3.2 9.0 ± 2.6 11.0 ± 4.3 0.15
 Proximal site PMA, mm2   7.9 ± 3.2 8.0 ± 2.8 10.7 ± 4.3 0.064
 Lesion VA, mm2   13.2 ± 4.0* 14.3 ± 4.0 17.6 ± 5.0 0.004
 Lesion LA, mm2   4.0 ± 1.9* 4.4 ± 1.9 5.7 ± 2.0 0.016
 Lesion PMA, mm2   9.2 ± 3.4 9.9 ± 3.3 11.9 ± 5.2 0.063
 Distal site VA, mm2   10.8 ± 3.4* 12.0 ± 3.9 15.6 ± 3.2 <0.001
 Distal site LA, mm2   6.1 ± 2.1 6.5 ± 2.0 6.9 ± 2.2 0.45
 Distal site PMA, mm2   4.7 ± 2.4* 5.5 ± 2.8 8.8 ± 2.9 <0.001
  1. Data provided as mean ± SD or number (%)
  2. ACC/AHA American College of Cardiology and American Heart Association, ACE-I angiotensin converting enzyme inhibitors, AMI acute myocardial infacrtion, AP stable angina pectoris, ARB angiotensin receptor blockers, CRP C-reactive protein, DES drug-eluting stent, DM diabetes mellitus, DS% diameter stenosis percentage, EF ejection fraction, HDL-C high density lipoprotein cholesterol, IVUS intravascular ultrasound, LA lumen area, LAD left anterior descending artery, LCX left circumflex artery, LDL-C low density lipoprotein cholesterol, MLD minimal lumen diameter, PMA plaque-media area, RCA right coronary artery, UAP unstable angina pectoris, VA vessel area
  3. *p<0.05, compared to unchanged stents